Todd Alonzo, PhD
Professor of Research Population and Public Health Sciences; Group Statistician for Children's Oncology Group
Todd Alonzo is a Professor of Research in the Department of Preventive Medicine, University of Southern California. He received his undergraduate degree at the California State Polytechnic University, San Luis Obispo, California in Statistics in 1994 and received both his MS and his PhD in Biostatistics in 1997 and 2000 from the University of Washington, Seattle. Dr. Alonzo's main areas of research interest are the statistical methods for analysis of biomarkers and medical diagnostic and screening tests, clinical trials, and the design and analysis of pediatric acute myelogenous leukemia studies. He has published over 245 peer-reviewed articles.
Dr. Alonzo has been member of the Editorial Board for Biometrics, Pediatric Blood Cancer, and Biometrical Journal and has acted as a reviewer for 30 scientific journals. He is a member of several Data Safety and Monitoring Boards. Dr. Alonzo was the President of the International Biometric Society Western Northern America Region (WNAR) in 2009. He is a Fellow of the American Statistical Association.
- Statistical Methods
- Research Design and Methods
Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia.
Haematologica. 2023 Feb 23;. doi: 10.3324/haematol.2022.281653. Epub 2023 Feb 23. PubMed PMID: 36815378;
Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia.
J Clin Oncol. 2023 Feb 16;:JCO2201114. doi: 10.1200/JCO.22.01114. Epub 2023 Feb 16. PubMed PMID: 36795987;
Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology Group.
Pediatr Blood Cancer. 2023 Feb 15;:e30251. doi: 10.1002/pbc.30251. Epub 2023 Feb 15. PubMed PMID: 36789545;
SAMHD1 Single Nucleotide Polymorphisms Impact Outcome in Children with Newly Diagnosed Acute Myeloid Leukemia.
Blood Adv. 2023 Jan 23;. doi: 10.1182/bloodadvances.2022009088. Epub 2023 Jan 23. PubMed PMID: 36689724;
CREBBP Alterations are Associated with A Poor Prognosis in de novo AML.
Blood. 2023 Jan 12;. doi: 10.1182/blood.2022017545. Epub 2023 Jan 12. PubMed PMID: 36634304;
- Design of Clinical Studies